Month: November 2015

  • Vital-Signs Sensors Built Into Ingestible Capsule

    19 November 2015. Engineering and medical researchers developed and tested in pigs a swallowed capsule with sensors that records heart and respiratory rates in real time. The team from the bioengineering lab of Robert Langer and Lincoln Laboratory at Massachusetts Institute of Technology published its proof-of-concept results yesterday in the journal PLOS One. The technology from…

  • Genomic, Patient Data Integrated for Precision Medicine

    18 November 2015. A collaboration of genomic profiling and software companies plans to integrate their services to provide what they call more informed precision medicine treatment options for cancer patients. Financial aspects of the agreement between genetic diagnostics enterprise Caris Life Sciences in Irving, Texas and software provider Syapse in Palo Alto, California were not…

  • Brain Tissue Banks Partner on Autism Research

    18 November 2015. Two repositories of brain tissue for research on neurological disorders agreed to coordinate their donation and distribution policies for studies of autism. The agreement aims to bring into alignment policies and practices of NeuroBioBank at National Institutes of Health and Autism BrainNet, a private tissue bank. The deal covers brain tissue samples…

  • Nanotech Sensors Devised for RNA Cancer Detection

    17 November 2015. Biochemical and medical researchers developed a technique for sensitive detection of RNA in humans that in lab tests can distinguish between benign conditions and cancer. The team from the lab of chemistry professor Rajesh Sardar at Indiana University-Purdue University Indianapolis published its findings in this month’s issue of the journal ACS Nano.…

  • Exosome Therapy Start-Up Launches, Raises $80M

    17 November 2015. A new biotechnology company developing therapies that use tiny cellular containers to deliver their payloads is spun off from M.D. Anderson Cancer Center and raising $80 million in early venture funding. Codiak Biosciences, based in Cambridge, Massachusetts is founded and licensing research by Raghu Kalluri, chair of M.D. Anderson’s cancer biology department.…

  • Study Explores Quality of Life for Dogs with Arthritis

    16 November 2015. The veterinary medicines company Zoetis is sponsoring a study of pain management and quality of life in dogs with osteoarthritis, using a mobile health monitor worn by the dogs. The 900 dogs serving as subjects in the study will wear the health monitor collar made by Voyce, known officially as i4C Innovations,…

  • Licensing, Research Deal Aims at Chronic Wound Treatments

    16 November 2015. Umeå University and the pharmaceutical company Prometic are partnering on development of new treatments for chronic wounds, such as diabetic foot ulcers and bed sores. The agreement gives Prometic, in Laval, Quebec, Canada an exclusive license to the university’s research on the blood plasma protein plasminogen, with the company funding further studies…

  • Less-Invasive Skin Biopsy Sought in $30K Challenge

    13 November 2015. In a new challenge on InnoCentive, a pharmaceutical company specializing in skin disorders is seeking a new minimally-invasive procedure for skin biopsies to provide samples for RNA analysis. The competition, sponsored by Leo Pharma in Ballerup, Denmark has a purse of $30,000 and a deadline of 10 February 2016. InnoCentive in Waltham,…

  • Penn, Epic Sciences Partner on Liquid Biopsies

    13 November 2015. University of Pennsylvania’s medical school plans to apply liquid biopsy technology developed by Epic Sciences to gain a more detailed understanding of different cancers for individual patient therapies. Financial terms of the agreement between the university and the San Diego biotechnology company were not disclosed. Epic Sciences’s technology detects and analyzes circulating…

  • Alliance Plans Adaptive Clinical Trials for Brain Cancer

    12 November 2015. A global collaboration plans a series of clinical trials that address precise molecular targets testing treatments for glioblastoma multiforme, an aggressive brain cancer. The alliance combines medical teams, researchers, and patient advocates to employ adaptive clinical trials, a type of clinical study that enables investigators to adjust research tactics as results with…